Bruce Freeman, PhD
Bruce Freeman, PhD, is a biochemist and pharmacologist who investigates eukaryotic cell production and actions of reactive inflammatory and signal transduction mediators (e.g., superoxide, nitric oxide, peroxynitrite, electrophilic lipids). He is currently the Irwin Fridovich Professor and Chairman of the Department of Pharmacology and Chemical Biology at the University of Pittsburgh School of Medicine and is a member of Pitt’s Vascular Medicine Institute and Cancer Institute. Of relevance to Complexa, his laboratory discovered that metabolic and inflammatory reactions of unsaturated fatty acids yield electrophilic nitro and keto derivatives of unsaturated fatty acids, products that manifest potent anti-inflammatory and tissue-protective signaling actions. His many groundbreaking discoveries and a substantial body of work in this space have led to numerous issued patents and more than 250 peer-reviewed publications in high-impact basic science and clinical journals.
Previously, Bruce was a Professor of Anesthesiology, Biochemistry and Molecular Genetics and Environmental Health Sciences at the University of Alabama at Birmingham (UAB). He was also Vice Chair for Research in the Department of Anesthesiology and Director of the UAB Center for Free Radical Biology. Prior to service at UAB, Bruce trained at the University of California and Duke University, where he also served on the faculty. He has been the recipient of a number of honors, including being named a Fulbright Research Scholar and serving as an invited lecturer at Nobel Forums. He and his lab team have secured more than $40 million in external funding to support their research activities.
Margaret Tarpey, MD
Margaret Tarpey, MD, is a former Professor of Anesthesiology and Pharmacology at the University of Pittsburgh School of Medicine and brings a clinical dynamic to the founding scientists of Complexa. Her academic research interests in the reactions of nitric oxide and oxygen radicals in cardiovascular diseases, combined with her operating room and ICU-based clinical experience, make her a perfect fit as the company elucidates the clinical safety and mechanisms of action of Complexa’s proprietary compound. Margaret received a BS in Biochemistry from the University of California, Riverside, an MS in Physiology and Pharmacology from the University of California, San Diego and then went on to receive her medical training at Duke University. Meg then completed her residency and fellowship in Anesthesiology at the University of South Carolina and the University of Alabama at Birmingham, where she practiced medicine and conducted laboratory-based research.